NCT01144975

Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

A Randomized Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: XOMA (US) LLC · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study hypothesis is that XOMA 052 is likely to improve glycemic control in subjects with Type 2 Diabetes Mellitus. The purpose of this study is to determine whether XOMA 052 improves glycemic control in subjects on Metformin monotherapy whose diabetes is still not adequately controlled.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	XOMA 052	Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
DRUG	Placebo	Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2010-06-16
• Last updated: 2012-05-16

Locations

1 site across 1 country: Mexico